Kanaph Therapeutics Inc.

Kanaph Therapeutics Inc., a biotech company, engages in drug development activities that include drug discovery and early-stage clinical trials in South Korea and the United States. The company's therapeutic platform includes bi-specific antibodies, Fc-fusions, and small molecules. It develops KNP-101, a FAP-targeted interleukin-12 cytokine, which is in preclinical stage for the treatment of solid tumors with an immunosuppressive tumor microenvironment; KKNP-301, a bispecific Fc-fusion protein that combines a C3b blocker and a VEGF blocker therapy for patients with wet age-related macular degeneration and geographic atrophy, which has completed preclinical stage; KNP-502, a dual antagonist of the prostaglandin E2 receptors EP2 and EP4 that is in Phase 1 clinical trials to overcome PGE2-mediated immunosuppression within the tumor microenvironment; KNP-503, a SHP2 allosteric inhibitor, which is in preclinical trials for the treatment of various KRAS-mutated cancers, including non-small cell lung cancer, colorectal cancer, and glioblastoma; and KNP-504, a SOS1 inhibitor, which has completed preclinical trials for the treatment of RAS-mutated cancers, including non-small cell lung cancer, colorectal cancer, pancreatic ductal adenocarcinoma, and NF1-mutant solid tumor. It also discovers KNP-701, an anti-cMET and anti-EGFR bispecific ADC for treating non-small cell lung cancer. Kanaph Therapeutics Inc. was founded in 2019 and is headquartered in Seoul, South Korea.